Stocks Health care APVO
NASDAQ · Health careAptevo Therapeutics Inc. (APVO)
It posted a net loss of $26.4M. At June 30, 2026 it held $9.8M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 14, 2026.
Key facts about Aptevo Therapeutics Inc.
- Net worth
- Aptevo Therapeutics Inc. has a market value (market cap) of $1.4M at the latest share price, and shareholders' equity of $6M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Cash flow
- In fiscal 2025 operations used $25.6M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 14, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Aptevo Therapeutics Inc.'s next report was expected around November 5, 2026 and is not on file with the SEC yet.
What Aptevo Therapeutics Inc. does
Aptevo Therapeutics Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker APVO.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$26M | -$87.27 | n/a |
| 2024 | n/a | -$24.1M | -$31,460.23 | n/a |
| 2023 | n/a | -$17.4M | -$834,149.74 | n/a |
| 2022 | $3.1M | $8M | $922,264.15 | -$21.1M |
| 2021 | $12.3M | -$28.5M | -$3,565,696.44 | -$22.4M |
| 2020 | $4.3M | -$17.8M | -$3,072,255.75 | -$29.4M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Aptevo Therapeutics Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 25, 2026
- September 24, 2026Other event 8-K
- September 23, 2026
- September 3, 2026Other event 8-K
- August 31, 2026Proxy statement DEF 14A
- August 21, 2026Preliminary proxy statement PRE 14A
- August 21, 2026IPO registration S-1
- August 21, 2026
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 14, 2026
Insider trades
What the people running Aptevo Therapeutics Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| August 6, 2026 | Niederhuber JohnDirector | Exercised options | 400 | - |
| August 6, 2026 | Kunz Barbara LopezDirector | Exercised options | 400 | - |
| August 6, 2026 | Abdun-Nabi DanielDirector | Exercised options | 400 | - |
| August 6, 2026 | White Marvin LExecutive Chair, Director | Exercised options | 1,666 | - |
| August 6, 2026 | White Marvin LExecutive Chair, Director | Shares withheld for tax | 406 | $1.7K |
| August 6, 2026 | Grant Grady IIIDirector | Exercised options | 400 | - |
| August 6, 2026 | Huebner DirkSVP, CMO | Exercised options | 638 | - |
| August 6, 2026 | Huebner DirkSVP, CMO | Shares withheld for tax | 156 | $634.9 |
Who owns APVO
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Niowave, Inc.13G, passive | 12.2% | June 22, 2026 |
| Ayrton Capital LLC13G, passive with 2 related filers | 10% | August 13, 2025 |
| YA II PN, Ltd.13G, passive with 7 related filers | 9.99% | July 8, 2025 |
| Bigger Capital Fund L P13G, passive with 2 related filers | 9.95% | June 25, 2025 |
| CVI Investments, Inc.13G, passive with 1 related filers | 6.3% | August 14, 2026 |
Largest institutional holders
Insiders
10 insiders reported holding 6,730 shares in total, about $5.2K at the last price.
| Holder | Shares |
|---|---|
| White Marvin LExecutive Chair, Director | 1,261 |
| Grant Grady IIIDirector | 1,150 |
| Lamothe Jeffrey G.President and CEO, Director | 961 |
| Kwon SoYoungSVP, GC, BD & Corp Affairs | 638 |
| Taylor DaphneSVP, CFO | 638 |
| Huebner DirkSVP, CMO | 482 |
| Niederhuber JohnDirector | 400 |
| Abdun-Nabi DanielDirector | 400 |
| Kunz Barbara LopezDirector | 400 |
| Harsanyi ZsoltDirector | 400 |
Questions about APVO
What does Aptevo Therapeutics Inc. do?
Aptevo Therapeutics Inc. is a company in the Health care sector, listed on NASDAQ as APVO. Its shares trade on NASDAQ under the ticker APVO.
What is Aptevo Therapeutics Inc.'s net worth?
Aptevo Therapeutics Inc. has a market value (market cap) of $1.4M at the latest share price, and shareholders' equity of $6M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Aptevo Therapeutics Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $26.4M.
When did Aptevo Therapeutics Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 14, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the employee stock plan registration from September 25, 2026.
When is Aptevo Therapeutics Inc.'s next earnings report?
Aptevo Therapeutics Inc.'s next report was expected around November 5, 2026 and is not on file with the SEC yet.
Similar companies
Compare APVO with
Follow APVO
Get an email when Aptevo Therapeutics Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Aptevo Therapeutics Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.